Attached files

file filename
EX-32.1 - EX-32.1 - Arcus Biosciences, Inc.rcus-ex321_10.htm
EX-31.2 - EX-31.2 - Arcus Biosciences, Inc.rcus-ex312_7.htm
EX-31.1 - EX-31.1 - Arcus Biosciences, Inc.rcus-ex311_6.htm
EX-23.1 - EX-23.1 - Arcus Biosciences, Inc.rcus-ex231_11.htm
EX-10.28 - EX-10.28 - Arcus Biosciences, Inc.rcus-ex1028_207.htm
EX-10.27 - EX-10.27 - Arcus Biosciences, Inc.rcus-ex1027_83.htm
EX-10.26 - EX-10.26 - Arcus Biosciences, Inc.rcus-ex1026_82.htm
EX-10.25 - EX-10.25 - Arcus Biosciences, Inc.rcus-ex1025_81.htm
EX-10.24 - EX-10.24 - Arcus Biosciences, Inc.rcus-ex1024_49.htm
EX-10.09 - EX-10.09 - Arcus Biosciences, Inc.rcus-ex1009_175.htm
EX-4.02 - EX-4.02 - Arcus Biosciences, Inc.rcus-ex402_244.htm
10-K - 10-K - Arcus Biosciences, Inc.rcus-10k_20191231.htm

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Arcus Biosciences, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date:     March 5, 2020

By:

 

/s/ Jason Barker

 

 

 

Jason Barker

 

 

 

Principal Financial & Accounting Officer